1026567-54-3

Upstream product

• 196810-28-3 <2-(4-fluorophenyl)-5-methyloxazol-4-yl>acetic acid methyl ester 
• 105983-77-5 methyl 4-bromo-3-oxopentanoate 
• 824-75-9 p-fluorobenzamide 
• 123-08-0 4-hydroxy-benzaldehyde 
• 196810-30-7 2-[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]ethanol 

Downstream Products

• 1027325-34-3 N-(4-{2-[2-(4-Fluoro-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-benzyl)-hydroxylamine 

Relevant academic research and scientific papers

Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones

A series of 1,2,4-oxadiazolidine-3,5-diones was synthesized and evaluated as oral antihyperglycemic agents in the obese insulin resistant db/db and ob/ob mouse - the two models for Type 2 diabetes mellitus. The majority of the prepared methoxy- and ethoxy-linked oxazole 1,2,4-oxadiazolidine-3,5-diones normalized plasma glucose levels at the 100 mg kg-1 oral dose in the db/db diabetic mouse model, and several amongst them reduced the glucose levels at the 20 mg kg-1 oral dose. The most potent compounds in the db/db mouse model were also active in the ob/ob mouse model normalizing the plasma glucose levels at the 20 mg kg-1 oral dose. The trifluoromethoxy analog 32 was the most active compound of the series, reducing significantly the plasma glucose levels at the 5 mg kg-1 oral dose. Oxadiazole-tailed 1,2,4-oxadiazolidine-3,5-diones were also active in both the db/db and ob/ob diabetic mouse models normalizing plasma glucose levels at the 100 mg kg-1 oral dose.

Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5- lipoxygenase

Azole phenoxy hydroxyureas are a new class of 5-lipoxygenase (5-LO) inhibitors. Structure-activity relationship studies have demonstrated that electronegative substituents on the 2-phenyl portion of the oxazole tail increased the ex vivo potency of these